Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid Tumors
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02476123 |
Recruitment Status :
Completed
First Posted : June 19, 2015
Last Update Posted : June 11, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Solid Tumor | Biological: Mogamulizumab: KW-0761, Nivolumab: (ONO-4538/BMS-936558) | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 118 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase 1 Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid Tumors |
Study Start Date : | June 2015 |
Actual Primary Completion Date : | February 7, 2018 |
Actual Study Completion Date : | December 21, 2018 |

Arm | Intervention/treatment |
---|---|
Experimental: Mogamulizumab+Nivolumab
During parts 1 and 2, Mogamulizumab and Nivolumab are administered at appropriate intervals. Part 1 (Dose Escalation Part) During Cohort 1 to 2, Mogamulizumab and Nivolumab are administered in combination. Part 2 (Expansion Part) Patients will be treated with maximum tolerated dose established in the dose escalation part for each combination. |
Biological: Mogamulizumab: KW-0761, Nivolumab: (ONO-4538/BMS-936558)
i.v. administration |
- Number of subjects reporting adverse events [ Time Frame: From the first dose of study medications until 90 days after the last dose of study medication ]
- Number of subjects reporting serious adverse events [ Time Frame: From the first dose of study medications until 90 days after the last dose of study medication ]
- Percentage of subjects reporting serious adverse events [ Time Frame: From the first dose of study medications until 90 days after the last dose of study medication ]
- Percentage of subjects reporting adverse events [ Time Frame: From the first dose of study medications until 90 days after the last dose of study medication ]
- Number of subjects experiencing dose-limiting toxicity [ Time Frame: For 28 days from the first dose of study medications ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subjects who voluntarily signed and dated Institutional Review Board approved informed consent form in accordance with regulatory and institutional guidelines.
- Subjects who have progressed or have been intolerant to any standard treatment regimen or refused standard treatment, or for which adequate standard therapy does not exist.
- Subjects who have evaluable lesion per guideline of Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
- Subjects with life expectancy > 12 weeks.
- Subjects with Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1.
- Potential child-bearing female who has agreed with contraception and not breast-feeding. For male who also has agreed with contraception.
- Subjects who have adequate hematological, renal, hepatic and respiratory functions defined.
- Must agree to present archival tumor tissues to sponsor or be willing to undergo a pre-treatment biopsy.
- Histologically or cytologically confirmed locally advanced or metastatic solid tumors.
Exclusion Criteria:
- Female subjects who are pregnant or breast-feeding.
- Subjects with uncontrolled and significant inter-current illness.
- Subjects with known central nervous system (CNS) metastases and/or carcinomatous meningitis.
- Subjects who have been previously treated with an anti-programmed death 1 (PD-1), anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
- Subjects who have been previously treated with Mogamulizumab.
- Subjects with any prior Grade ≥ 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE.
- Subjects with a history of severe hypersensitivity reactions to drugs.
- Subjects who have been received chemotherapies, immunotherapy, biologic or hormonal therapies, another investigational drug, radiation or major surgery for cancer treatment within 28 days or 42 days (for nitrosourea or mitomycin C) prior to Cycle 1 Day 1.
- Subjects who have known active autoimmune disease or syndrome.
- Subjects who have active inflammatory bowel disease, irritable bowel disease, celiac disease, or other serious GI chronic conditions associated with diarrhea.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02476123
Japan | |
Chiba, Japan | |
Tokyo, Japan |
Responsible Party: | Kyowa Kirin Co., Ltd. |
ClinicalTrials.gov Identifier: | NCT02476123 |
Other Study ID Numbers: |
0761-013 |
First Posted: | June 19, 2015 Key Record Dates |
Last Update Posted: | June 11, 2019 |
Last Verified: | June 2019 |
Neoplasms Nivolumab Mogamulizumab Antineoplastic Agents, Immunological |
Antineoplastic Agents Immune Checkpoint Inhibitors Molecular Mechanisms of Pharmacological Action |